News in Brief
Pharmacology - May 29
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery
Pharmacology - May 29
Novartis Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Novartis Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
![[Simulation] In 2022, the pews will replace the chairs dating from 1912. © Canto](/news/wire/an_epfl_lab_designs_new_wooden_pews_for_the_lausanne_cathedral-2020-epfl/image_h150.jpg)
Life Sciences - May 28
Genetics of nuptial coloration facilitates the persistence of co-occurring species
Genetics of nuptial coloration facilitates the persistence of co-occurring species
wire - news in brief
« BACK
Health - Pharmacology - 30.05.2020
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 29.05.2020
Pharmacology - Health - 28.05.2020
Pharmacology - Health - 28.05.2020
Pharmacology - Health - 27.05.2020
Pharmacology - Health - 27.05.2020
Health - Pharmacology - 19.05.2020
Pharmacology - Health - 19.05.2020
Pharmacology - Health - 14.05.2020
Pharmacology - 07.05.2020 
Flowbone can help prevent bone fractures caused by osteoporosis
EPFL scientists have developed a gel that can locally reinforce bones weakened by osteoporosis. The startup they created, called Flowbone, has just made it through the second round of the Venture Kick competition. Femoral neck fractures occur frequently among the elderly, and are usually caused by osteoporosis - a disease that weakens the bone structure.
Pharmacology - Health - 06.05.2020
Pharmacology - Health - 01.05.2020
Pharmacology - Health - 29.04.2020
Pharmacology - Economics / Business - 28.04.2020
Pharmacology - Health - 23.04.2020 
Possible coronavirus drug: university pharmacists produce generic medication
In response to a lack of potential coronavirus medications on the market, pharmacists from the University of Basel have begun to produce tablets themselves.
Health - Pharmacology - 23.04.2020 
Trial Launched to Test Prophylactic Treatments for COVID-19 Contact Persons
With the easing of measures, there is a pressing need for tools and approaches to contain potential new COVID-19 outbreaks.
Pharmacology - Health - 22.04.2020
Pharmacology - Health - 22.04.2020
Pharmacology - Health - 21.04.2020
Pharmacology - Health - 20.04.2020
Pharmacology - Health - 17.04.2020
Pharmacology - Health - 16.04.2020
Health - Pharmacology - 06.04.2020 
EPFL launches a series of projects to combat the Coronavirus crisis
EPFL researchers have been working for weeks to help fight the pandemic and mitigate its shortand long-term consequences. Studies are already under way on methods to stem the spread of the virus, diagnose the disease and discover a vaccine. EPFL researchers are also part of an EU initiative called PEPP-PT to develop an app that can identify people who have been in contact with a coronavirus carrier.
Health - Pharmacology - 03.04.2020 
Coalition Launched to Accelerate Research on the Prevention and Treatment of COVID-19 in Low- and Middle-Income Countries
A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings.
Pharmacology - Health - 02.04.2020
Pharmacology - Economics / Business - 02.04.2020
Health - Pharmacology - 31.03.2020
Pharmacology - Health - 28.03.2020
Pharmacology - Health - 27.03.2020
Pharmacology - Health - 27.03.2020
Health - Pharmacology - 26.03.2020 
"In a crisis like this, an antiviral drug could buy us some time"
Francesco Stellacci, a professor in EPFL's School of Engineering, discusses his research in the field of nanomedicine and how it could help us get past the coronavirus crisis.
Pharmacology - Economics / Business - 26.03.2020
Pharmacology - Health - 24.03.2020
Pharmacology - Health - 24.03.2020
Pharmacology - 23.03.2020
Pharmacology - Health - 20.03.2020
Pharmacology - Health - 19.03.2020
Pharmacology - Health - 18.03.2020
Pharmacology - Health - 17.03.2020
Health - Pharmacology - 13.03.2020 
Heading home with a rehab robot
Hands are our most important tools. Many stroke survivors struggle with a serious loss of function in their affected hand. ETH researchers are developing innovative solutions to help people in rehabilitation - and in everyday life. Hands are our most important tools. Many stroke survivors struggle with a serious loss of motor function in their affected hand.
Health - Pharmacology - 13.03.2020 
"We take rehabilitation to also mean inclusion."
ETH Zurich aims to step up rehabilitation research and education with the Rehab Initiative. But how are the needs of people with disabilities best met' To discuss the issues, we hosted a roundtable with a physician, a person with a disability and a researcher.
Health - Pharmacology - 11.03.2020
Pharmacology - Health - 03.03.2020
Pharmacology - Economics / Business - 02.03.2020
Health - Pharmacology - 27.02.2020
Pharmacology - Health - 25.02.2020
Pharmacology - Health - 24.02.2020
Pharmacology - Health - 17.02.2020
Pharmacology - Health - 11.02.2020
Pharmacology
Results 1 - 50 of 1399.
Switzerland's lockdown has sharply reduced the cases of COVID-19
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
EPFL researchers have modeled the effects of measures taken in the country to slow the spread of coronavirus. According to their estimates, the contamination rate has fallen by between 53% and 92%, depending on the canton, and people's movements have been reduced by 30% to 80%. Have the Swiss government's lockdown measures been effective in stemming the pandemic? That's the question a team of EPFL researchers set out to answer by analyzing data dating back to 28 February, the day the Swiss government banned groupings of over 1,000 people.
Novartis announces new late-breaking ofatumumab data at EAN demonstrating robust efficacy and safety in the treatment of relapsing forms of multiple sclerosis (RMS)
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
Rapid and profound depletion of B-cells contributed to a halt in disease activity in RMS patients 1 A post hoc analysis showed 47.0% and 87.8% of patients treated with ofatumumab achi
EPFL scientists have developed a gel that can locally reinforce bones weakened by osteoporosis. The startup they created, called Flowbone, has just made it through the second round of the Venture Kick competition. Femoral neck fractures occur frequently among the elderly, and are usually caused by osteoporosis - a disease that weakens the bone structure.
Novartis Cosentyx gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum
Cosentyx is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) d
Cosentyx is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA) d
In response to a lack of potential coronavirus medications on the market, pharmacists from the University of Basel have begun to produce tablets themselves.
With the easing of measures, there is a pressing need for tools and approaches to contain potential new COVID-19 outbreaks.
Novartis Kymriah receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults
Novartis announces data showing Jakavi (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond
Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond
Novartis announces new Mayzent (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed M
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed M
EPFL researchers have been working for weeks to help fight the pandemic and mitigate its shortand long-term consequences. Studies are already under way on methods to stem the spread of the virus, diagnose the disease and discover a vaccine. EPFL researchers are also part of an EU initiative called PEPP-PT to develop an app that can identify people who have been in contact with a coronavirus carrier.
A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings.
Novartis new analysis further shows durable and potent LDL-C reduction with inclisiran, an investigational first-in-class siRNA cholesterol-lowering treatment
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipo
Patients & Caregivers Healthcare Professionals Society & ESG Prespecified analysis of pooled data from ORION-9, -10 and -11 Phase III clinical trials shows inclisiran reduced low-density lipo
Novartis Cosentyx gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum
Patients & Caregivers Healthcare Professionals Society & ESG EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is
Patients & Caregivers Healthcare Professionals Society & ESG EMA CHMP positive opinion in non-radiographic axial spondyloarthritis (nr-axSpA) paves way for fourth indication in Europe, and is
Francesco Stellacci, a professor in EPFL's School of Engineering, discusses his research in the field of nanomedicine and how it could help us get past the coronavirus crisis.
Zolgensma data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth
Patients & Caregivers Healthcare Professionals Society & ESG Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma (onasemnogene abeparvovec-xioi) soon after birth
Hands are our most important tools. Many stroke survivors struggle with a serious loss of function in their affected hand. ETH researchers are developing innovative solutions to help people in rehabilitation - and in everyday life. Hands are our most important tools. Many stroke survivors struggle with a serious loss of motor function in their affected hand.
ETH Zurich aims to step up rehabilitation research and education with the Rehab Initiative. But how are the needs of people with disabilities best met' To discuss the issues, we hosted a roundtable with a physician, a person with a disability and a researcher.
COVID-19: IRB receives EU emergency research funding
Following the publication of a ¤10 million call in January, the European Commission has secured an additional ¤37.5 million for urgently needed research on COVID-19 vaccine development, treatment and diagnostics.
Following the publication of a ¤10 million call in January, the European Commission has secured an additional ¤37.5 million for urgently needed research on COVID-19 vaccine development, treatment and diagnostics.
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Patients & Caregivers Healthcare Professionals Society & ESG FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping
Patients & Caregivers Healthcare Professionals Society & ESG FDA Priority Review for capmatinib based on Phase II data in first-line and previously treated patients with MET exon 14 skipping
News in Brief
Pharmacology - May 29
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar + Mekinist following surgery
Pharmacology - May 29
Novartis Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Novartis Piqray receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation
Life Sciences - May 28
Genetics of nuptial coloration facilitates the persistence of co-occurring species
Genetics of nuptial coloration facilitates the persistence of co-occurring species